CN85103712B - Blood cell separating agent and its preparation - Google Patents
Blood cell separating agent and its preparation Download PDFInfo
- Publication number
- CN85103712B CN85103712B CN198585103712A CN85103712A CN85103712B CN 85103712 B CN85103712 B CN 85103712B CN 198585103712 A CN198585103712 A CN 198585103712A CN 85103712 A CN85103712 A CN 85103712A CN 85103712 B CN85103712 B CN 85103712B
- Authority
- CN
- China
- Prior art keywords
- separating agent
- blood cell
- cell separating
- blood
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to a blood cell separating agent which comprises 2 to 12 wt% of sodium carboxymethyl starch, 0.1 to 5 wt% of anticoagulant, 0 to 5 wt% of glucose, 0 to 0.9 wt% of sodium chloride and water, wherein the anticoagulant can comprise one or more than one of heparin, disodium ethylene diamine tetraacetate, citric acid, citrate, lactate, phosphate, etc.; the water can be distilled water. The components are arbitrarily mixed, stirred, decolorized by active carbon, filtered and sterilized to form the blood cell separating agent. The blood cell separating agent can be used for blood component transfusion, production of food with high protein content and manufacture of blood biological products.
Description
The invention belongs to a kind of blood cell separating agent.This blood cell separating agent contains carboxymethyl starch sodium, and this blood cell separating agent can be divided into blood two parts, and a part is containing leukocyte and platelet; Another part is containing erythrocyte.
In modern medicine, component blood transfusion is that the one of commonly using is treated disease method.The needs of patients of for example various aleucemias supplements leukocyte, should not accept too much erythrocyte.This will be defeated by patient with the leukocyte that blood cell separating agent separates in blood, and remaining erythrocyte can defeatedly be returned blood donor or exsanguine patient.Conventional blood cell separating agent has: polyvinyl alcohol, and carboxymethyl cellulose, macromolecule hetastarch, (Chinese tallow tree is celebrating " blood preservation " to macromolecule dextrorotation candy acid anhydride, the first edition P218 of Science and Technology of Shanghai publishing house, 1981; Rock forever etc., immune と blood 4 (1).51，1982)。What this class material had directly inputs the change that can cause blood circulation dynamics in body as macromolecule dextrorotation candy acid anhydride, and sensitization, and the leukocyte suspension after therefore separating need can be applied through eluting repeatedly.What have is as expensive in macromolecule hetastarch, separates required time longer, enters in body excretion slower.
The object of this invention is to provide one inexpensive efficient, the blood cell separating agent having no side effect.
The present invention is the compound method of a kind of blood cell separating agent that contains carboxymethyl starch sodium and this compound recipe carboxymethyl starch sodium blood cell separating agent.
Blood cell separating agent of the present invention is the carboxymethyl starch sodium by 2-12% (weight), the anticoagulant of 0.1-5% (weight), the glucose of 0-5% (weight), sodium chloride and the water of 0-0.9% (weight) form.The formula of recommending is the carboxymethyl starch sodium containing 4-10% (weight), the anticoagulant of 0.1-3% (weight), and the glucose of 2-5% (weight), the sodium chloride of 0-0.9% (weight), all the other are water.Described anticoagulant can be one or more heparin, disodiumedetate, and the institutes such as citrate, lactate, phosphate form.Preferably distilled water of described water.
The compound method of compound recipe carboxymethyl starch sodium blood cell separating agent of the present invention, is that the material of said components is mixed arbitrarily, and activated carbon decolorizing after stirring filters, then can apply through high temperature or microporous filter sterilization treatment.Activated carbon decolorizing preferably adopts the active carbon of 0.12% (weight), at 80 ° of-100 DEG C of temperature, decolours.
The blood cell separating agent that contains carboxymethyl starch sodium of the present invention more conventional blood cell separating agent, as macromolecule dextrorotation candy acid anhydride and macromolecule hetastarch etc., not only the source of goods is abundant, cost is lower, production and using method easy, and leukocyte separation rate is up to more than 80%.Platelet separation rate reaches 75%, and isolated red, leukocyte and hematoblastic physiological function are unaffected.Can be used for treating disease with the hemocyte that blood cell separating agent of the present invention separates, as separate the leukocyte that obtains and platelet can be defeated by suffer from leukopenia through chemistry or radiation treatment or burn and need the patient of transfusion, erythrocyte can be defeated by blood donor or anemia patient.The carboxymethyl starch sodium entering in body with hemocyte in this blood cell separating agent can be degraded, the 60-80% of its total amount can excrete at one day, therefore it is a kind of safe and effective, and the blood cell separating agent that using method is easy is particularly applicable in the poor medical institutions of appointed condition and battlefield.
The blood cell separating agent that contains carboxymethyl starch sodium of the present invention can be used for hemocyte and separate.Except a kind of purposes of the component blood transfusion for above-mentioned, the hemocyte also can be used in the production of blood biological product separates, and also can be used for the separation of slaughterhouse animal blood, prepares colourless blood cell protein, uses for producing high-protein food.
The using method of blood cell separating agent of the present invention is by mixed mutually to blood cell separating agent and blood, static rear blood layering.Wherein the weight ratio of blood cell separating agent and blood is 0.5-2.0.
Embodiment
The compound method of compound recipe carboxymethyl starch sodium blood cell separating agent is to get 3 parts of carboxymethyl starch sodium, 0.1 part of heparin, 1 part of glucose, 0.9 part, sodium chloride, 0.1 part of active carbon, all the other are heated to boil for water mixes, 80 °-100 DEG C of temperature, filter, high temperature or microporous filter sterilizing, blood cell separating agent.
Claims (4)
1. the preparation method of a blood cell separating agent, it comprises the mixing that adds water of each component taking carboxymethyl starch sodium as key component, through activated carbon decolorizing, filtration and degerming are processed and are made, it is characterized in that said component comprises the carboxymethyl starch sodium of 2-12% (weight), the anticoagulant of 01-5% (weight), the glucose of 0-5% (weight), the sodium chloride of 0-0.9% (weight), all the other are water, described decolouring is preferably used the active carbon of 0.1-2% (weight), under 80-100 DEG C of condition, completes.
2. the method for claim 1, wherein said anticoagulant can be one or more heparin, disodiumedetate, citric acid, citrate, lactate, phosphate.
3. the method for claim 1, wherein said water is distilled water.
4. the method for claim 1, wherein said blood cell separating agent is when it is during for human body hemocyte, and the weight ratio of blood cell separating agent and blood is 0.5-2.0.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN198585103712A CN85103712B (en) | 1985-05-13 | 1985-05-13 | Blood cell separating agent and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN198585103712A CN85103712B (en) | 1985-05-13 | 1985-05-13 | Blood cell separating agent and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN85103712A CN85103712A (en) | 1986-11-12 |
| CN85103712B true CN85103712B (en) | 1987-10-21 |
Family
ID=4793389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN198585103712A Expired CN85103712B (en) | 1985-05-13 | 1985-05-13 | Blood cell separating agent and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN85103712B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100336829C (en) * | 2003-02-26 | 2007-09-12 | 戴连宝 | Carboxymethyl starch sodium preparation, preparing process and use thereof |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104357387B (en) * | 2014-12-08 | 2017-02-22 | 深圳市赛欧细胞生物科技有限公司 | Method for separating human adipose-derived stem cells from human adipose tissues |
| CN107617236A (en) * | 2017-09-28 | 2018-01-23 | 安徽信灵检验医学科技有限公司 | A kind of platelet rich liquid |
-
1985
- 1985-05-13 CN CN198585103712A patent/CN85103712B/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100336829C (en) * | 2003-02-26 | 2007-09-12 | 戴连宝 | Carboxymethyl starch sodium preparation, preparing process and use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN85103712A (en) | 1986-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wexler et al. | III. The Fate of Citrate in Erythroblastotic Infants Treated with Exchange Transfusion | |
| US3928135A (en) | Process for the production of glucose polymers | |
| US3984539A (en) | Bovine immunoglobulin isolation process | |
| CN103864950B (en) | A kind of preparation method and applications of low molecule Porphyra haitanensis polysaccharide iron complexes | |
| US5112865A (en) | Pharmaceutical compositions containing a derivative of 3-hydroxybutanoic acid chosen from oligomers of this acid and esters of this acid or of these oligomers with 1,3-butanediol | |
| DE3150318C2 (en) | "Process for the preparation of a polysaccharide derivative of fibrinolysin" | |
| CN104857088A (en) | Preparation method of mulberry leaf compound capsule for lowering blood glucose in assistant manner | |
| DE2635065C2 (en) | Process for the semi-continuous treatment of whole blood for the production of biologically active hematopoietic chalon extracts | |
| RU2040932C1 (en) | Preparation influencing tissular metabolism and application of fusarium sambucinum fuckel var ossicolum (berkiet curf) bilai fungus strain to produce the preparation | |
| US20040146565A1 (en) | First lipoprotein fraction and therapeutic compositions of same | |
| CN85103712B (en) | Blood cell separating agent and its preparation | |
| Dole | A Dialyzable Medium for Cultivation of Group A Hemolytic Streptococci. | |
| RU2618467C1 (en) | Normalization method of trombocytes catalase activity of newborn calves with iron deficiency | |
| JPH0450293B2 (en) | ||
| RU2041717C1 (en) | Biologically active remedy, method for its producing, preparation containing the mentioned remedy and its application method | |
| DE19726626C1 (en) | Preparation of composition comprising purified hyaluronidase | |
| CN1190205C (en) | Diemailing injection and its preparing process | |
| AT392003B (en) | METHOD FOR PRODUCING A PARTICULARLY FOR Wounds Healing Or For Treatment In Geriatrics, Active Ingredients From Mammalian Blood By PAPAINE HYDROLYSIS AND A PREPARATION CONTAINING SUCH AN ACTIVE SUBSTANCE | |
| KR20020031404A (en) | Blood plasma replacement solution | |
| CN109010367A (en) | Bovine colostrum and preparation method thereof, preparation and the application in preparation tumor | |
| CN117338748B (en) | Capsule for treating atrial and ventricular premature beat and its preparing process | |
| RU2108797C1 (en) | Method of dna-base antiviral preparation preparing | |
| DE69531103T2 (en) | PREVENTIVE AGENT FOR CIRCULAR DISEASES | |
| DE3341760C2 (en) | ||
| JPH04334322A (en) | Antineoplastic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| PB01 | Publication | ||
| C06 | Publication | ||
| C13 | Decision | ||
| GR02 | Examined patent application | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |